Your browser doesn't support javascript.
loading
Comparison of Piperacillin/Tazobactam Dosing (13.5 g/day vs. 18 g/day) for the Treatment of Hospital-Acquired Pneumonia and Ventilator-associated Pneumonia in Intensive Care Unit
Korean Journal of Clinical Pharmacy ; : 167-173, 2018.
Article in Korean | WPRIM | ID: wpr-717151
ABSTRACT

BACKGROUND:

In July 2016, the Infectious diseases society of america and the american thoracic society (IDSA & ATS) published a guideline recommending piperacillin/tazobactam (Pip/Tazo) 18 g/day as the anti-pseudomonal dose for the treatment of pathogenic pneumonia. After the guideline was published, the Pip/Tazo dose used for the treatment of pathogenic pneumonia was changed from 13.5 g/day to 18 g/day in a superior general hospital intensive care unit (ICU). In this study, we analyzed the effectiveness and safety of the new dose.

METHODS:

Adult patients aged ≥19 years who were diagnosed with pneumonia in ICU and who received Pip/Tazo for 7 days or more from September 1, 2015 to May 31, 2017 were included in the study. The electronic medical record (EMR) was retrospectively analyzed.

RESULTS:

At baseline, there was a significant difference between 44 patients treated with 13.5 g/day and 31 patients treated with 18 g/day of Pip/Tazo. The 18 g/day-treatment group comprised more elderly patients than the 13.5 g/day-treatment group (p=0.028). The results of the treatment-effects analysis showed no significant difference between the two groups. In case of safety data, there were significant differences in two parameters related to blood count, namely hemoglobin (p=0.016) and platelet count (p=0.011).

CONCLUSION:

Based on the significant difference in baseline age, there is a possibility that high-dose Pip/Tazo showed improved therapeutic effect. However, when high-dose Pip/Tazo was used, the blood cell count was found to drop from the reference value more frequently. Therefore, blood cell count should be monitored carefully when high-dose Pip/Tazo is administered.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Piperacillin / Platelet Count / Pneumonia / Reference Values / Blood Cell Count / Americas / Communicable Diseases / Retrospective Studies / Critical Care / Pneumonia, Ventilator-Associated Type of study: Practice guideline / Observational study / Risk factors Limits: Adult / Aged / Humans Language: Korean Journal: Korean Journal of Clinical Pharmacy Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Piperacillin / Platelet Count / Pneumonia / Reference Values / Blood Cell Count / Americas / Communicable Diseases / Retrospective Studies / Critical Care / Pneumonia, Ventilator-Associated Type of study: Practice guideline / Observational study / Risk factors Limits: Adult / Aged / Humans Language: Korean Journal: Korean Journal of Clinical Pharmacy Year: 2018 Type: Article